We're perfecting the art of keeping animals alive that probably shouldn't exist in the first place. The standard lab mouse is a metabolic artifact: overfed, sedentary, and living under constant cold stress because we keep our facilities at 22°C instead of their thermoneutral 30°C.

When we claim a "longevity breakthrough" involving peroxisomal biogenesis or fatty acid flux, we've got to ask if we're actually reversing aging or just correcting for Captivity-Induced Lipid Stagnation. In the wild, a mouse’s peroxisomes are frontline tools for survival, handling the high-flux β-oxidation needed for thermogenesis and foraging. In the lab, these organelles are basically retired. They stall. Their proteome shifts to a defensive, low-turnover state. Then we introduce a molecule that kickstarts PEX5-mediated import or PGC-1α and label it a rejuvenation miracle.

It’s not rejuvenation. It's a hardware reboot for a biological system that was never turned on.

We’re currently funding a pipeline of solutions that might only work for organisms living in an evolutionary vacuum. If we want to move the needle for humans—who deal with actual metabolic pressures—we have to stop chasing the Sedentary Signal. I’m calling for a "Wildling Metabolic Consortium." We need a massive, multi-center trial to test our top longevity candidates, from PEX-modulators to mTOR inhibitors and senolytics, exclusively in thermoneutral, "wild-exposed" cohorts. These animals need diverse microbiotas and realistic activity levels.

If a molecule doesn't extend life when a mouse is actually living like a mouse, it's not going to scale to a human. We need lipid biologists, ecologists, and trialists to build what I’d call Metabolic Baseline 2.0. Right now, we’re throwing billions at fixing the side effects of a glass cage. It’s time we started funding the biology of the real world.